Navigation Links
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
Date:11/18/2010

ood tolerability of AEZS-108 was also reflected by a low rate of severe possibly drug-related non-hematological adverse events and which included single cases (2.4%) each of nausea, diarrhea, fatigue, general health deterioration (Grade 4), creatinine elevation, and blood potassium decrease. No cardiac toxicity was reported. Conclusion

  • AEZS-108 at a dosage of 267 mg/m2 every 3 weeks was active and well tolerated in patients with endometrial cancer.
  • Hematological toxicity was rapidly reversible, and non-hematological toxicities were usually not severe, causing few deviations from scheduled treatment.
  • The objective response rate of 31% compares well with those of single agent platinum or taxane treatment; responders included patients pre-treated with platinum/taxane combination.
  • In addition, the rate of stable disease was 44%, resulting in a Clinical Benefit Rate of 74%.
  • The overall survival after single agent AEZS-108 is similar to that reported for modern triple combination chemotherapy, but was achieved with lower toxicity. 
  • The abstract is available at: cr="true" href="http://www.aezsinc.com/temp/poster378.html">http://www.aezsinc.com/temp/poster378.html About Endometrial Cancer This year, the American Cancer Society estimates that more than 43,000 cases of endometrial cancer - tumors in the lining of the uterus and the glands of the endometrium - will be diagnosed in the United States. Symptoms can include unexplained vaginal bleeding, painful urination, painful intercourse and soreness in the pelvic area. There is no routine test to identify endometrial cancer. Treatment options include surgery, radiation therapy, hormone therapy and chemotherapy; however, there are new treatments in development that work by targeting and destroying cancerous cells. About AEZS-108 AEZS-108 represents a new targeting concept in
    '/>"/>

    SOURCE AETERNA ZENTARIS INC.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
    2. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
    3. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
    4. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
    5. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
    6. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
    7. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
    8. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
    9. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
    10. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
    11. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... Global Stem Cells Group and ... to conduct Turkey’s first ever stem cell harvesting and ... alliance with Stem Cell Training, Inc. and in conjunction ... M.D. will conduct the Adipose and Bone Marrow ... , Tiryaki, a renowned plastic surgeon practicing in London ...
    (Date:6/3/2015)... (PRWEB) June 03, 2015 On April 21, ... Energy, Utilities and Communications Committee (11-0) and indicates the legislature's ... and renewable energy. , The Committee Chairman supports the bill ... the CAP by 8,000 GWh and would also like to ... list. , This “Wait List” and timing are extremely ...
    (Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
    (Date:6/3/2015)... Latham, NY (PRWEB) June 03, 2015 ... of Silicon Avalanche Photodiodes. Marktech APD’s have an internal ... high sensitivity in the near infrared region. These APD’s ... where internal gain is needed to overcome high pre-amp ... a standard photodiode and are ideal for extreme low-level ...
    Breaking Biology Technology:Global Stem Cells Group subsidiary Stem Cell Training Announces First Training Course to Take Place in Turkey 2Global Stem Cells Group subsidiary Stem Cell Training Announces First Training Course to Take Place in Turkey 3Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Marktech Introduces New Line of APDs 2
    ... Healthcare (NYSE: SI ) has appointed Gregory ... Healthcare in the U.S.A., effective June 1.  Sorensen succeeds ... Sorensen will also oversee the Canadian activities of Siemens ... Sorensen will be responsible for leading the marketing, ...
    ... FRANCISCO, May 12, 2011 Jennerex, Inc., a private ... of first-in-class targeted oncolytic products for cancer, today announced ... study in advanced liver cancer patients, along with data ... the American Society of Gene and Cell Therapy (ASGCT) ...
    ... MATEO, Calif., May 11, 2011 Nile Therapeutics, ... develops novel therapeutics for heart failure patients, today announced that ... Market effective with the open of business on May 12, ... under the "NLTX" symbol on the OTCQB Marketplace following the ...
    Cached Biology Technology:Gregory Sorensen to Head Siemens Healthcare U.S. and Canada Organizations 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 3Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 4Nile Therapeutics to Transition to OTCQB Marketplace 2Nile Therapeutics to Transition to OTCQB Marketplace 3
    (Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
    (Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
    (Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
    Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
    ... RICHLAND, Wash. A new computer simulation has ... that may lead to development of radiation-resistant materials ... Researchers at the Department of Energy,s Pacific ... of oxygen atoms heals radiation-induced damage in the ...
    ... clearly that powerful starquakes ripple around the Sun in the ... The observations give solar physicists new insight into a long-running ... other stars. The outermost quarter of the Suns interior ... this region causes ripples that criss-cross the solar surface, making ...
    ... have discovered that increasing age affects the way breast cancer ... less likely to be diagnosed with aggressive tumours that have ... is increasingly likely to spread, particularly if the tumours are ... aging and lymph node involvement and this study is the ...
    Cached Biology News:Ceramic, heal thyself 2Solar flares set the Sun quaking 2Breast cancers behave differently before and after the age of 70 2Breast cancers behave differently before and after the age of 70 3
    Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
    ... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
    ... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
    ... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: barcoded ...
    Biology Products: